Key facts
- Mediar Therapeutics’s last known valuation is $230.0M (Dec 2025).
- It has raised $180.3M across 3 recorded rounds; the latest was Early Stage VC ($37.8M) in Dec 2025.
- Notable investors include Kinled Holding, Sofinnova Partners, Mission BioCapital, ShangBay Capital, Pfizer Ventures — 21 tracked in total.
- Mediar Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently Oct 2024 ($85.0M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Mediar Therapeutics
Funding rounds
3 roundsAbout Mediar Therapeutics
Developer of innovative fibrosis treatment intended for halting and reversing fibrotic activity. The company utilizes antibodies to neutralize mediators that contribute to the development of chronically damaged organs, thereby improving patient outcomes and advancing therapeutic options, enabling medical practitioners to address late-stage disease with precision and efficacy.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 49
- Website
- mediartx.com/
- Ownership
- Privately Held (backing)
Mediar Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mediar Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mediar Therapeutics in its N-PORT filings yet. We sweep new filings monthly.